Innoviva (INVA) Current Deferred Revenue (2010 - 2026)
Innoviva's (INVA) quarterly Current Deferred Revenue came in at $3.7 million in Q1 2026, up 266.97% YoY from $1.0 million in Q1 2025, and down 13.89% on a QoQ basis from $4.3 million in Q4 2025.
Innoviva (INVA) Current Deferred Revenue (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 13 years of Current Deferred Revenue data on file, last reported at $3.7 million in Q1 2026.
- Quarterly Current Deferred Revenue rose 266.97% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 million (up 266.97% YoY) and the FY2025 annual result came in at $4.3 million, up 279.22% from the prior year.
- Current Deferred Revenue eased to $3.7 million in Q1 2026, from $4.3 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $13.6 million in Q3 2025 to a low of $717000.0 in Q3 2024.
- A 5-year average of $2.8 million and a median of $2.1 million in 2022 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue slumped 73.72% — and 2025, when it soared 1792.75%.
- Tracing INVA's Current Deferred Revenue over 5 years: stood at $2.1 million in 2022, then sank by 39.02% to $1.3 million in 2023, then declined by 11.82% to $1.1 million in 2024, then surged by 279.22% to $4.3 million in 2025, then declined by 13.89% to $3.7 million in 2026.
- The last three Current Deferred Revenue figures came in at $3.7 million (Q1 2026), $4.3 million (Q4 2025), and $13.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.02 Mn |
| Mar 31, 2026 | 3.68 Mn |
| Dec 31, 2025 | 4.27 Mn |
| Sep 30, 2025 | 13.57 Mn |
| Jun 30, 2025 | 3.13 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 1.13 Mn |
| Sep 30, 2024 | 717,000.00 |
| Jun 30, 2024 | 855,000.00 |
| Mar 31, 2024 | 987,000.00 |
| Dec 31, 2023 | 1.28 Mn |
| Sep 30, 2023 | 1.55 Mn |
| Jun 30, 2023 | 3.25 Mn |
| Mar 31, 2023 | 2.09 Mn |
| Dec 31, 2022 | 2.09 Mn |
| Sep 30, 2022 | 2.85 Mn |
| Sep 30, 2017 | 885,000.00 |
| Jun 30, 2017 | 885,000.00 |
| Mar 31, 2017 | 885,000.00 |
| Dec 31, 2016 | 885,000.00 |